CompletedNCT00216476
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
Medication studyAges 18+Multiple countries
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Hall in Tirol and 95 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 753
- Sponsor
- Janssen-Cilag International NV
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Austria, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT00216476
- Official title
Show the full official title
CONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness
Get this study by email
Recruitment & locations
CompletedHall in Tirol, Austria · Linz, Austria · Neunkirchen, Austria
95 more locations
- Pleven, Bulgaria
- Sofia, Bulgaria
- Sofia Sofia, Bulgaria
- Osijek, Croatia
- Rijeka, Croatia
- Split, Croatia
- Zagreb, Croatia
- Brno, Czechia
- Lnáře, Czechia
- Opava, Czechia
- Pardubice, Czechia
- Plzen Czechia, Czechia
- Prague, Czechia
- Praha 2 N/A, Czechia
- Uherský Brod, Czechia
- Ústí nad Labem, Czechia
- Middelfart, Denmark
- Vordingborg, Denmark
- Pÿrnu N/A, Estonia
- Tallinn, Estonia
- Tartu, Estonia
- Bron, France
- Brumath, France
- Créteil, France
- Dieppe, France
- Hénin-Beaumont, France
- Mont-Saint-Martin, France
- Poitiers, France
- Reims, France
- Roubaix, France
- Toulouse, France
- Augsburg, Germany
- Berlin, Germany
- Bochum, Germany
- Duisburg, Germany
- Düsseldorf, Germany
- Karlstadt am Main, Germany
- Krefeld, Germany
- München, Germany
- Oranienburg, Germany
- Stralsund, Germany
- Heraklion -Crete, Greece
- Thessalonikis, Greece
- Budapest, Hungary
- Gyõr, Hungary
- Gyula, Hungary
- Kistarcsa, Hungary
- Szeged, Hungary
- Vác, Hungary
- Cork, Ireland
- Dublin, Ireland
- Kerry, Ireland
- Sligo, Ireland
- Jerusalem, Israel
- Ramat Gan, Israel
- Tel Aviv, Israel
- Jelgava, Latvia
- Riga, Latvia
- Alytus, Lithuania
- Kaunas, Lithuania
- Klaipėda, Lithuania
- Šiauliai, Lithuania
- Vilnius, Lithuania
- Choroszcz, Poland
- Gdynia Na, Poland
- Poznan, Poland
- Warsaw, Poland
- Coimbra, Portugal
- Porto, Portugal
- Bucharest, Romania
- Craiova, Romania
- Iași, Romania
- Khobar, Saudi Arabia
- Košice, Slovakia
- Zvolen, Slovakia
- Begunje na Gorenjskem, Slovenia
- Ljubljana, Slovenia
- Ormoz, Slovenia
- Madrid, Spain
- Oviedo (Asturias), Spain
- Seville, Spain
- Valencia, Spain
- Gothenburg, Sweden
- Trollhättan, Sweden
- Ankara Turkey, Türkiye
- Bakirkoy/Istanbul N/A, Türkiye
- Istanbul, Türkiye
- Izmir, Türkiye
- Barnet, United Kingdom
- Barnsley, United Kingdom
- Hull, United Kingdom
- Llantrissant, United Kingdom
- Swansea, United Kingdom
- Czechia
- Türkiye
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag International NV.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole, Risperidone Long Acting Injectable (LAI) and Quetiapine.
Who was this study for?
Listed age limits: from 18 years.
Want to explore more studies?
Explore studiesRelated studies
A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia